In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Conjugate Palopegteriparatide | Natural fragment Teriparatide (PTH 1-34) | |
|---|---|---|---|
| Identity | |||
| Kind | Conjugate | Natural fragment | |
| Area | Recovery and repair | Recovery and repair | |
| Evidence | |||
| Amount of evidence | 210 | 2,709 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 49 (48 in people) | 209 (168 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 10 · 5 active1 more mentions it but does not test it | 168 · 15 active30 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Yorvipath says: “Treatment of hypoparathyroidism in adults”
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Palopegteriparatide | Teriparatide (PTH 1-34) |
|---|---|---|
| Bone and jointMusculoskeletal | 1313 | 2,228128691326 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Forteo says: “The active N-terminal fragment of parathyroid hormone, approved for osteoporosis in selected patients”
| Adverse eventsWhole body | 44431 | 16313726 |
|---|
| Electrolyte balanceEndocrine and hormones | 50437 | 3030 |
|---|
| PainMusculoskeletal | 11 | 6262 |
|---|
| Kidney functionKidney and urinary | 28235 | 27243 |
|---|
| PharmacokineticsPharmacology | 844 | 30273 |
|---|
| Quality of lifeWhole body | 1515 | 1313 |
|---|
| Exercise and physical functionWhole body | 77 | 1818 |
|---|
| Treatment adherence and retentionWhole body | 22 | 66 |
|---|
| SleepSleep | 11 | 11 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Palopegteriparatide is the same as Teriparatide residues 1 to 34, with 1 added group.
What is different
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 10 trials, ranked by phase, then posted results and enrollment: 1 ongoing · 2 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)
Ascendis Pharma Bone Diseases A/S84 participants16 Feb 2021 to 21 Jan 2025
Hypoparathyroidism · Endocrine System Diseases · Parathyroid Diseases
Visen Pharmaceuticals (Shanghai) Co., Ltd.81 participants28 Jul 2021 to 8 Jan 2026
Hypoparathyroidism · Parathyroid Hormone Deficiency · Endocrine System Diseases · Parathyroid Diseases
Ascendis Pharma Bone Diseases A/S36 participants7 May 2026 to est. Jun 2028
Hypoparathyroidism · Endocrine System Diseases · Parathyroid Diseases
1 more mentions it but does not test it. They only measure it or name it in their text.
Top 3 of 168 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Radius Health, Inc.2,463 participantsApr 2011 to Oct 2014
Osteoporosis · Postmenopausal Osteoporosis
Eli Lilly and Company1,366 participantsOct 2012 to Jul 2016
Postmenopausal Osteoporosis
Eli Lilly and Company712 participantsJun 2006 to Jun 2010
Osteoporosis, Postmenopausal · Back Pain · Spinal Fracture
30 more mention it but do not test it. They only measure it or name it in their text.
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | Palopegteriparatide | Teriparatide (PTH 1-34) |
|---|---|---|
| Adverse eventsMusculoskeletalCompared as: value in the arm that got the peptide, in % | 82% Adverse events · TransCon PTH, 50/61 Placebo, 21/21: 100% Dose studied: initially 18 μg/d, titrated26 weeksn = 822023 | 86.7% Adverse events Placebo: 86.1% Dose studied: 28.2 μg once weeklyn = 3162014 |
82%
Adverse events · TransCon PTH, 50/61
Placebo, 21/21: 100%
Dose studied: initially 18 μg/d, titrated26 weeksn = 822023
86.7%
Adverse events
Placebo: 86.1%
Dose studied: 28.2 μg once weeklyn = 3162014
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Palopegteriparatide | Teriparatide (PTH 1-34) |
|---|---|---|
| Exercise and physical functionMusculoskeletalCompared as: value in the arm that got the peptide, in s | No comparable result 1 randomized-trial result measure it in another way or another unit. | −3.2 to −5.9 s TUG time difference versus risedronate · teriparatide minus risedronate, 6 to 26 weeks |
| Electrolyte balanceEndocrine and hormonesCompared as: value in the arm that got the peptide, in % | 79% participants meeting composite primary endpoint at week 26 · TransCon PTH group, 48/61 Placebo group, 1/21: 5% Dose studied: initially 18 μg/d, titrated26 weeksn = 822023 | No comparable result 9 randomized-trial results measure it in another way or another unit. |
|---|
| Kidney functionKidney and urinaryCompared as: value in the arm that got the peptide, in mg/24-hour | 390 mg/24-hour Urine calcium Placebo baseline: 329 mg/24-hour Dose studied: 18 mcg/d26 weeksn not reported2022 | No comparable result 12 randomized-trial results measure it in another way or another unit. |
|---|
| PainMusculoskeletalCompared as: difference from placebo, in % | No randomized trial result 1 result from other study designs. | −31% Relative risk reduction · Shown as a change. The study reports a relative risk reduction of this size. Dose studied: 20 microgmedian 19 monthsn = 1,0852005 |
|---|
| Bone and jointMusculoskeletalCompared as: value in the arm that got the peptide, in % | No randomized trial result 13 results from other study designs. | 7.2% Lumbar spine BMD change Dose studied: 20 microg once daily18 monthsn = 4282007 |
|---|
No comparable result
1 randomized-trial result measure it in another way or another unit.
−3.2 to −5.9 s
TUG time difference versus risedronate · teriparatide minus risedronate, 6 to 26 weeks
Dose studied: 20 μg every day78 weeksn = 1712017
79%
participants meeting composite primary endpoint at week 26 · TransCon PTH group, 48/61
Placebo group, 1/21: 5%
Dose studied: initially 18 μg/d, titrated26 weeksn = 822023
No comparable result
9 randomized-trial results measure it in another way or another unit.
390 mg/24-hour
Urine calcium
Placebo baseline: 329 mg/24-hour
Dose studied: 18 mcg/d26 weeksn not reported2022
No comparable result
12 randomized-trial results measure it in another way or another unit.
No randomized trial result
1 result from other study designs.
−31%
Relative risk reduction · Shown as a change. The study reports a relative risk reduction of this size.
Dose studied: 20 microgmedian 19 monthsn = 1,0852005
No randomized trial result
13 results from other study designs.
7.2%
Lumbar spine BMD change
Dose studied: 20 microg once daily18 monthsn = 4282007